Get the Stockscreener App
0.1883
0.26%
-0.0005
After Hours:
.19
0.0017
+0.90%
Tonix Pharmaceuticals Holding Corp stock is traded at $0.1883, with a volume of 20.95M.
It is down -0.26% in the last 24 hours and up +13.78% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$0.1888
Open:
$0.1926
24h Volume:
20.95M
Relative Volume:
0.59
Market Cap:
$35.98M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-0.0101
EPS:
-18.6875
Net Cash Flow:
$-114.09M
1W Performance:
-0.89%
1M Performance:
+13.78%
6M Performance:
-96.65%
1Y Performance:
-98.80%
1-Day Range:
$0.184
$0.199
1-Week Range:
$0.1685
$0.212
52-Week Range:
$0.118
$22.14
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
0.1883 | 35.98M | 0 | -121.02M | -114.09M | -18.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharma talks NDA for Fibromyalgia drug, FDA decision on NDA acceptance expected December 2024 - Proactive Investors USA
Tonix Pharmaceuticals Holding (FRA:TPM0) Effect of Exchange Rate Changes : €-0.03 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference - The Manila Times
Tonix Pharmaceuticals to Present Pipeline Updates, $34M DoD Contract at NobleCon20 | TNXP Stock News - StockTitan
Monkey Pox Treatment Market Advancements Highlighted by Growth, Size & Forecast 2024-2033 - WhaTech
Tonix Pharmaceuticals Holding (STU:TPM0) Free Cash Flow : €-63.32 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) EV-to-Revenue : 0.99 (As of Nov. 20, 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Enterprise Value : $10.87 Mil (As of Nov. 20, 2024) - GuruFocus.com
Can Tonix Pharma's TNX-102 SL End The 15-Year Drug Drought In Fibromyalgia? - RTTNews
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual - The Manila Times
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - The Manila Times
Tonix Pharmaceuticals Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology Convergence 2024 Annual Meeting - Marketscreener.com
Tonix Pharmaceuticals to Present Pipeline Updates at Winter 2024 Investor Summit | TNXP Stock News - StockTitan
TNXP (Tonix Pharmaceuticals Holding) Interest Coverage : N/A (As of Jun. 2024) - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in Tonix Pharmaceutica - GuruFocus.com
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments - AccessWire
KEMRI partners with US firm Tonix Pharmaceuticals to develop mpox vaccine - The Eastleigh Voice News
Tonix reports less virulent mpox vaccine candidate - Investing.com India
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - The Manila Times
Tonix Pharma to Present Key Fibromyalgia Drug Data, Awaits FDA Decision on Fast-Tracked Treatment | TNXP Stock News - StockTitan
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals - The Manila Times
Tonix's TNX-801 Vaccine Shows Breakthrough Safety Results, 1000x More Effective Than Legacy Vaccines | TNXP Stock News - StockTitan
Tonix Pharma earnings beat by $2.70, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tonix Pharmaceuticals Files FDA Application for First New Fibromyalgia Drug in 15 Years | TNXP Stock News - StockTitan
Tonix Pharma Unveils Promising TNX-1700 Cancer Data - TipRanks
Tonix presents new data on TNX-801 mpox vaccine - BioWorld Online
Tonix Pharma Partners for Vaccine Clinical Trial - Yahoo Finance
Tonix Pharmaceuticals Holding Corp. Announces Research Agreement with Kenya Medical Research Institute to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - Marketscreener.com
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - The Manila Times
Tonix Pharmaceuticals (TNXP) Earnings Date and Reports 2024 - MarketBeat
Tonix reports promising mpox vaccine candidate data By Investing.com - Investing.com South Africa
Tonix reports promising mpox vaccine candidate data - Investing.com
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 - The Manila Times
Tonix Pharmaceuticals CEO Discusses New Drug Application for Fibromyalgia Treatment - Proactive Investors UK
Tonix Pharmaceuticals Holding (LTS:0A4T) PE Ratio (TTM) : At Loss (As of Oct. 29, 2024) - GuruFocus.com
Tonix Pharmaceuticals to Present at BIO-Europe® 2024 - StockTitan
Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference - StockTitan
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024 - Yahoo Finance
Tonix Pharmaceuticals Holding (FRA:TPM0) Purchase Of Proper - GuruFocus.com
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency - Marketscreener.com
Tonix Pharma gets DoD contract for antiviral development - Investing.com
Tonix Pharma Secures Defense Contract for Antiviral Development - TipRanks
Tonix Pharma gets DoD contract for antiviral development By Investing.com - Investing.com UK
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) - The Manila Times
Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance
Tonix Pharmaceuticals files NDA for fibromyalgia drug - Investing.com
Tonix Pharmaceuticals files NDA for fibromyalgia drug By Investing.com - Investing.com UK
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) - Yahoo Finance
Tonix Pharmaceuticals Partners with X-Chem for AI-Driven Antiviral Development - MSN
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):